Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Astera Labs (ALAB) has drawn fresh attention after reporting second quarter 2026 results and issuing new third quarter guidance, giving investors updated figures on sales, profitability, and expected revenue.
See our latest analysis for Astera Labs.
At a share price of $320.17, Astera Labs has seen a strong 90 day share price return of 31.08% and a year to date share price return of 78.31%. The 1 year total shareholder return of 71.74% points to momentum that has been reinforced by recent earnings and third quarter guidance, as well as visibility from its August presentations at the OCP APAC Summit.
If the recent move in Astera Labs has you looking across AI infrastructure, this could be a useful moment to scan other opportunities through our screener of 56 AI infrastructure stocks
After a near vertical run on the back of strong 2026 figures, the real question for Astera Labs investors now is simple. Is most of the move already in the rearview mirror, or does the valuation still leave meaningful upside?
Astera Labs is trading at $320.17 against a most widely followed fair value estimate of about $391.77, so the narrative sees meaningful upside from current levels.
Rapid ramp-up and continued customer diversification of the Scorpio P-Series and soon-to-launch Scorpio X-Series switches are driving increased dollar content per AI accelerator, establishing a higher baseline for revenues as Astera Labs moves from early product adoption to large-scale rack-level AI infrastructure deployments, which will materially impact top-line growth and revenue stability.
Want to understand why this fair value leans higher than today's price? The narrative focuses on ambitious revenue expansion, robust margins, and a rich future earnings multiple that many investors will want to unpack for themselves.
Result: Fair Value of $391.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Astera Labs still faces concentration risk around large hyperscaler customers and rapid technology shifts that could pressure pricing power and make current earnings assumptions harder to achieve.
Find out about the key risks to this Astera Labs narrative.
The fair value narrative around Astera Labs leans on long term earnings forecasts and premium P/E assumptions. A simpler yardstick, the current P/S ratio of 46.2x, paints a more demanding picture. It is higher than the US Semiconductor industry at 7.7x, peer average at 18.4x, and even the fair ratio of 44x. That gap suggests less room for error if growth or margins fall short. How comfortable are you paying such a premium for this story?
To see how this price tag compares when you break the ratios down, See what the numbers say about this price — find out in our valuation breakdown.
There is plenty to like and question in the Astera Labs story, so treat this as a prompt to move fast and test the assumptions yourself. A balanced view means weighing both the upside and the concerns that other investors are already focused on through the 2 key rewards and 3 important warning signs.
If Astera Labs has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to quickly spot other targeted ideas before they move.
Target stability by checking out 80 resilient stocks with low risk scores to help keep portfolio swings in check while still offering growth potential.
Hunt for strong fundamentals through the solid balance sheet and fundamentals stocks screener (50 results) to help you focus on companies with financial resilience.
Spot potential early movers with the screener containing 19 high quality undiscovered gems before they show up on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALAB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]